Dhara N. Amin, Ph.D.
Affiliations: | 2003 | Yale University, New Haven, CT |
Area:
Molecular Biology, OncologyGoogle:
"Dhara Amin"Parents
Sign in to add mentor| David Frederick Stern | grad student | 2003 | Yale | |
| (Gene expression analysis of ErbB family signaling: Encodement of signaling specificity and identification of targets of ErB2 and ErbB4.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Campbell MR, Zhang H, Ziaee S, et al. (2016) Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Research and Treatment |
| Amin DN, Ruiz-Saenz A, Gulizia N, et al. (2015) Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 6: 41123-33 |
| Amin DN, Ahuja D, Yaswen P, et al. (2015) A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular Cancer Therapeutics. 14: 2805-17 |
| Park CC, Amin D, Zhang H, et al. (2014) Abstract 5438: Resistance to β1 integrin inhibition in HER2 amplified cancers is mediated by HER3 Cancer Research. 74: 5438-5438 |
| Amin DN, Ahuja D, Ducker GS, et al. (2013) Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers. Cancer Research. 73: 3043-3043 |
| Amin DN, Sergina N, Lim L, et al. (2012) HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. The Biochemical Journal. 447: 417-25 |
| Amin DN, Campbell MR, Moasser MM. (2010) The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Seminars in Cell & Developmental Biology. 21: 944-50 |
| Coma S, Amin DN, Shimizu A, et al. (2010) Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Research. 70: 3823-32 |
| Amin DN, Sergina N, Ahuja D, et al. (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science Translational Medicine. 2: 16ra7 |
| Campbell MR, Amin D, Moasser MM. (2010) HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy Clinical Cancer Research. 16: 1373-1383 |